OptiBiotix Health Share Chat (OPTI)

The sweetbiotix tasting will likely coincide or be shortly after the announcement of the 2025 results in June.

Just an inkling of a sweetbiotix contract and revenue and this explodes. But I have been saying this for ages and still holding!

I’m no longer in London, I’m based in Australia now so can’t attend this meeting. I’m looking forward to some feedback from other shareholders.

FS - 👍

Lords, hopefully we'll get to share a coffee at the investor day. Would be good to meet a few others too. Depending on the SP by then I'll either be the one in the Armani suit or the one in Primark Jeans

Maybe that’s it. I expected an email. We’ll see.

I’m having the same problem and the link to log out doesn’t work either. Had to just close it down. I’ll try and contact them.

I’m hopeful at long long last Sweetbiotix may finally become a commercial success.

I am registered and received an email this morning directly from the company

I’m already registered, but no separate email received from them yesterday or today. And no sign up link when Iclick through from the RNS.

Anyone else in the same position? And anyone since solved it?

Took 10 minutes for 4 digit email verification email to come through.

now signed up

Link is working but not receiving 4 digit email verification email

Not sure if anyone has posted this, but this podcast was posted on SOH's LinkedIn 3 days ago....

"Podcast of OptiBiotix which helps explain the reason for accessing the OTCB markets and plans for 2026 and beyond see https://lnkd.in/e527Frdi "

Sweetbiotix and all products discussed....worth a listen

I do think it’s viable, providing sales continue to grow - as is currently the trend - and their focus remains on relentless cost reduction.

The value of their remaining SBTX holding is unknown currently due to suspension. Their PBX holding could be boosted significantly overnight by migrating from Aquis which is a hopelesly illiquid & inappropriate exchange for Probiotix.

Touch and go. Even with costs reducing and revenue increasing (both to be confirmed when we get H1 figures in Sep), there will still be a deficit to fill. SBTX stake nearly gone thru, PBX a possible source of funds. How long will that last. What comes after that?

Disregarding any potential huge deals regarding Sweetbiotix, do you think Optibiotix is viable on the rest of its business eg Amazon, Opti US, Opti Asia?

Thank you FS. I always try to look at things objectively.

My current read of Opti is that it IS making progress and is now more focused than ever on cost control & sustainable sales growth.

But progress has been ridiculously slow compared to guidance - often one step forwards, two steps back.

In fairness to you though Lords, you at least understand the criticisms a few of us have of SOH in this regard.

“enough said” bang on toyin and all it tells me the ceo is full of bull****. did have a little chuckle to myself whilst watching it and thinking i actually believed most of that tosh.

Now Opti claims to have enough working capital until H1 2027, it really needs to pull its finger out with Sweet &/or sales of its existing ranges.

The family silver has largely been sold off now. And whilst I personally way prefer this source of funding to umpteen rights issues/placings, I don’t then want them coming cap in hand to shareholders, asking for yet more working capital funding.

I’ve never seen eye to eye with Friedman over Opti’s treatment of its SBTX holding.

That said, I agree with him that the February RNS should never have implied Opti wouldn’t be reducing its SBTX stake “currently”, when it then did just over 2 months later.

Funny how we were all only talking about this very issue & the Feb RNS earlier today!

As for Fried’s assertion that most of Opti’s SBTX sales have ultimately proved ill-timed, I’d take issue with that.

Time will tell with this latest reduction. But with SBTX currently suspended below 10p, unless some suitor comes along to snap it up at a significant premium, I’d say Opti was very well-advised to divest heavily,

They can't issue new shares as the resolution didn't pass at the last AGM

Hi,

Not sure I understand your logic Fried.

1. I cant see how you can describe it as a buyers market when the shares have been suspended pending an investigation which has been going on since the middle of February. It takes 3 months for a full external audit so there is some risk here.

2. I have reviewed all the RNS's and reports and cant see any comment saying that OPTI wouldnt sell SBTX shares. In fact to the contrary. The strategy to sell £7m of SBTX shares after buying for £650K is in virtually every annual report.

3. I cant see how you can link this to SweetBiotix. I suspect no existing shareholder would want OPTI to raise funds at the current SP. If you follow the market you will see it is very hard to raise funds (unless mining/oil etc) and discounts average 26% - with warrants. Selling SBTX has meant OPTI has not had the same shareholder dilution as SBTX or PBX

4. Finally, I am totally dumbfounded by you saying this si a great sign for SBTX holders. in a share that is suspended with an ongoing enquiry since mid Feb and it looks like another 2-4 weeks before we see anything.

I am a SBTX shareholder and I hope I am wrong but like others have mentioned this is looking very difficult for SBTX shareholders. Lest hope of betetr times ahead.

Fried i imagine they were approached for the stock otherwise if searching around they would have had to take much lower price to 9p. Topping up the cash whilst a stock asset you hold has just had its CEO fired for making up £700k of numbers fraudulently, is currently under investigation and has been suspended, provides a level of certainty to its own shareholders over funding. If everything is rosy at SBTX after this period they still have 5.7m shares to cash in future if SBTX recovers, its a balance of risk v's reward.

As for sweet I've recently seen on the opti website Q&A they have said everything is all proceeding as planned for H1.

Whilst you may be all in on SBTX no one knows what will happen. The facts we do know create massive uncertainty until resolved or otherwise.

Think choice of partner(s) is key. I got the impression that this endless delay with Sweet was because Opti went for initial partners that were too big and gave Opti no control (say?) over timescales.

Skid, agree they need a partner for scaling long term sales of sweetbiotix but this was about demonstrating a range of SweetBiotix products to investors in H1 2026, I presume from their own lab scale manufacturing capability. I take a spoonful of sugar in my tea and coffee, dislike the taste of artificial sweeteners, and hence would welcome sampling a sugar substitute version of sweetbiotix for myself and if i am unable to denote any off notes in my beverages, that would go along way to satisfy me about the quality of the product and likelihood of take-up by a Partner

Aquae - at about the same price SOH and the CFO were buying. Hopefully SOH knows something the market doesn't (and then doesn't completley over estimate what he has), but we've said that far, far too many times before.

On Sweet, they need a partner for volume and also to confirm that OPTI has in sweet has value rather than own brand / own store.

Expect nothing but can-kicking, could, would, should, according to this or that data, potentially, possibly, metric tonnes... bla bla bla.

Has his lad finished uni yet?

Lord, I have said previously that I sold at a loss around the 12p mark, however, I recognise the potential value of sweetbiotix and wont hesitate to buy back in if I feel the time is right, hence why I post and exchange opinions and views with others like yourself to gauge when that time might be.

Regarding the small launch of sweetbiotix for Investors to sample, I genuinely can't see what partner restrictions there could be for an own store launch of a sucrose based product, Opti own the patents and nothing, other than funding surely prevents such a venture with a number of small companies offering private label assistance such as BTS

https://www.bio-techsolutions.com/private-label-service/

Yes lol, my mistake. They were first listed as Ceres Media in 2011, then Ducat Ventures until August 2014 when;

Change of name to OptiBiotix Health plc

Ducat Ventures plc (AIM: DUC), which will become a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, confirms that it's proposed change of name to OptiBiotix Health plc has now been registered at Companies House and is therefore effective.

So nearly 12 years. Feels like decades.

DireCons - “After 15 years of jam tomorrow”.

Really? Opti only IPO’d on AIM in Aug 2014.

If you’re going to be a glass half empty kinda poster, at least stay factual. Unless of course you invested before it went public!

'This share seems to be constantly barraged with negative snipes by old holders'. Do you blame us? After 15 years of jam tomorrow, you would expect a bit of Wharreva!!

For the record, I haven't sold because it's not worth it. Just clinging on to the wreckage hoping a deal for the fabled 'Sweetbiotix' actually arrives before I die of old age.

Dire yet they continue to grow and have sales confirmed for 2026 already in January of over £800k so pretty nailed on for more growth this year with good and improving margins and large cost reductions. Clearly a few partners are coming to something. E-commerce was over £400k in 2024 which isn't included in the £800k or any orders received after the Jan release. They also have £100k royalty in H2 for SweetBiotix. On this basis alone they should on for £1.3-£1.5m for FY2026 already and anything else they receive in the next 8 months is more growth on top. Then the core business will look increasingly solid and will get very interesting when SweetBiotix launches.

This share seems to be constantly barraged with negative snipes by old holders. Just buy back in before the rerate from these levels and make some of your money back :)

Meanwhile, way back in March 2024;

RNS Number : 5803G

OptiBiotix Health PLC

13 March 2024

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this agreement with Morepen, a well-known and trusted supplier to pharmacies, physicians, and retail customers across India. Morepen brings an extensive sales team with experience of highly differentiated scientific products and countrywide access to a network of around 500,000 pharmacies across India. Based on current forecasts, the Directors anticipate this agreement could contribute in the region of £6-7 million revenue per annum in the next four to five years."

He could have said "It's dragging on and on, and it looks as though it will come to nothing, just like the vast majority of the partnerships that we've signed over the last 15 years."

Time ran out about 5 years ago. Just a lifestyle business for the OH family now.

Nb Commited revenue for 2026 looks like £1.5M to date so they need to double and get GP to 65% and they are at scratch

The auditors will want to see one years cash burn on hand to sign off going concern

Assume £160k a month burn they have £500k maybe £600k today

SOH never mentioned cash yesterday which was a pity and we can guess he didn’t want to flag so kept stum

If the SBTX stake is worth £600k and they dispose post suspension that’s the next 12 months burn covered and H2 could add almost £200K if production costs reduce 31% and GP hits 65% at that point

Ideally they then need £3M revenue to get to FCF neutral

Suggest that’s the maths

LIR -me neither.

Depends how cash & liquid asset position is presented to auditors. Also with increasing sales, margin & large reduction in costs these together will also be factored so don’t believe that will be the case.

Letitrun " With SBTX holding still worth £1.25m and if suspension lifts end of this month with no bad surprises that holding should increase in value further for a nice top up later this year." Opti will need to sell SBTX shares before June in order to avoid a qualification on their Accounts I suspect. Now as a SBTX holder I will be delighted if immediately following suspension the sp has reason to rocket, but may well take a little longer and that is time Opti does not have as the shareholders have removed the option of an equity raise and PBX remain illiquid

Use AI as most people do today to looks smart

Thanks Siouks

If I actually knew what you were saying I might bear it in mind.

Why? Because I name things as they are. You don't have to write a lot, post a lot. You just watch it for years as an investor with hope and open eyes for good news, then your £1 investment become worth less then 5p and what you can hope for? For a manipulated rise on a spike to 8p-10p.... let's be serious. Investment brings return in other way this is just so called one way sponsorship and have nothing to do with your hope. It is truly unfair tactic

Siouks - thanks for your latest insightful post which I’ve duly filed in the WPB.

Best of luck if you can find somewhere to short it.

Trouble is you can't trust the management not to sell down SBTX and PBX stakes if cash needed. They've done it before with Skin.

What Opti management own on top of the 30%

Some skin in the game here

You could see the PBX stake heading to be equal to Opti m/cap at this rate

SBTX is bunce on top / cash in hand

Core Opti is a free ride

4.1% stake

If Q1 2026 order book is £1.3m and at 54% gross margin that’s so £700k gross profit in a single quarter against total opex running at roughly £500k per quarter in 2025

Ballpark depreciation / share comp etc is £25k a qtr ?

Any comments

Opti own 30% of PBX

Key Highlights

· Sales +45% to £2.73m (2024: £1.88m)

· Gross Profit +46% to £1.48m (2024: £997,000)

· EBITDA loss from continuing operations down 34% to £426,000* (2024: £642,000*)

· Gross Profit margin improved to 54% (2024: 53%)

· Group remains fully funded with a cash balance of £1.27m

· 10 new products launched during the year

During Q1 2026 the Group has achieved profitability

· Outlook positive with a record Q1 2026 order book +110% at £1.3m

· Strong momentum in China, with increasing sales channels being delivered by partner Kemin China Technology

· Recent launch of new women's health products is gaining further tangible traction - well placed to target an accessible B2B market worth more than $5 billion

· Planned (and funded) expansion in new metabolic health areas to include prediabetes studies

· Further margin improvement has been achieved, driven by CMO optimisation

Whatever good news you bring here we are lower and in one direction

On track to share product with shareholders..

That's good to hear.

4. There is a lot of activity underway to ensure consistency of product manufacture and supply. We are on track to share product with shareholders in H1. I have kept this response general as specific information could be deemed as 'inside'.

Thanks to Andrew for asking

Thanks Martinu

Guess the one off legal costs re PBX is the unknown £ ?

Indeed mart, ironic really. They have a long way to get back to the 20p float price, so that could be a hindrance too.

DC, ironically the PBX shares on Aquis might hinder SOH selling the stake there. But would love shares to be on AIM.

Oke, I'm awaiting the TU to see if revenue shows a positive uplift compared to recent positive comments. Opti are still well away from break even. Think costs are £1.5-2m , so would need revenue of £4m ish with gross margin of 50%. Costs could have fallen a bit.

Only thing to add was cash raise of £750k in May 25. And would take any Dr M forecasts as very optimistic!

Last one

SA has 10% equity do has skin here, his salary is £140k

Appreciate any posters who can challenge the numbers / data below, handy to see if I am missing something ?

Set to 4.50... so there is lots of space to make money on the way down

And again.... making money on the way down not up... Still a lot of space till bottom. Shareholder value has nothing to do with sp price for a long time. No matter even what RNS they put out here... only one direction and only one way to get a value on investment here - shorting it

Martinu - I don’t think the current SP prices in any growth v LY (assuming there is some, which I fully expect).

Trading update timing has varied significantly in the past, so March this year is by no means a given.

If last year is anything to go by we should get an update soon. 18th March last year. Last two HY have had revenue of around £550k. Talk from SOH has been positive recently. If the talk is translated into numbers I'm hoping for continued progress and FY 25 revenue of perhaps £1.4m.

Bk2011 - agreed. And there’s no guarantee it’ll ever happen.

Conversely if it does - and you’ve been “waiting for a tangible launch” - you can expect to pay a whole heap more.

You pays your money (or waits) and takes your choice.

We've been here a number of times before with SOH saying a sweetbiotix launch is imminent/ on the cusp etc. I'm waiting for a tangible launch.

Yeah. I think the NDAs etc are more to ensure Opti safeguards its own IP, rather than protect the identity of partners it’s working with.

I know SOH has been twitchy about revealing partner details in the past. But maybe things have progressed sufficiently since for them to name

These companies have been named in an RNS by Opti before confirming all the majors are interested

“Partner agreements

The Company has been working with a wide range of industry partners since 2020 and has Material Transfer Agreements ("MTA"), and/or Non-Disclosure Agreements ("NDA"), and/or Open innovation arrangements with well-known consumer brands like Kellogg's, Nestle, Coca Cola, Cargill and more specialised sweetener and fibre groups like Tereos, Givaudan, Sudzucker, Puratos and Firmench. These agreements allow us to share information and products whilst protecting our intellectual property and partners to receive information and different SweetBiotix® products to test within their product ranges. This allows them to assess texture, taste, stability, and how they would incorporate Sweetbiotix® into their product manufacturing processes.”

Once they get manufacturing sorted which sounds like real progress is now being made this should rerate majorly. Pathetic market cap currently for existing business let alone what’s coming through.

I understand how it could be read like that but I think the ‘WITH THESE PARTNERS’ is more likely to refer to the part earlier where h talks about ‘some partners require…’ rather than the specific named companies given as an example of how Sweet will fit soft drinks.

I would be very surprised given the multiple times he has spoken about partners demanding confidentiality and therefore Opti not being able to tell us as much as we or they would like, if he were then able to just name those companies in an RNS. I think it’s SOH pulling his old trick of throwing huge names into the mix to get us going a bit.

That being said, regardless, it does explicitly state that it’s a globally leading brand so even if it isn’t the two titans, it should still be a huge positive if it works out.

Oke, I'm anticipating a trading update next week and it looks like some are buying in advance of this, with the depressed SP. If we get a decent uplift on FY revenues, I would hope the SP should get a good lift. Albeit that it might be a temporary opportunity.

PS the study could be very advantageous if positive .

OptiBiotix announced on 24/02 26 the commencement of a clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac surgery outcomes and potential NHS cost savings.

It is a double-blind, placebo-controlled study enrolling up to 60 participants, who will receive six weeks of pre-operative supplementation. Researchers will assess intensive care duration, total hospital stay, and post-operative complication rates, alongside a detailed economic analysis of potential NHS cost savings.

Previous studies (Ardema 2019, Xia 2021) suggested that reduced microbial diversity and abundance following surgery may increase hospital stays, and that prebiotics which enhance microbial diversity and exert systemic anti-inflammatory effects could improve surgical outcomes.

Notably, the Group has received NHS ethics approval and a grant with Hull University Teaching Hospital to run this study — meaning it is externally funded

Punchy quote off Steve

“If successful it could lead to WellBiome becoming the standard of care for NHS patients undergoing surgery.”

I bought more yesterday as I believe undervalued at this low SP.

Although SBTX has all the attention I think this will switch to here at some point.

I'll hold for SP recovery.

Thanks MU

Oke, I am a LTH, but with modest investment, though down plenty. FWIW, I would consider Opti a buy at these levels, but as a possible ST punt. There is always a risk with Opti where forecast revenue is concerned. I doubt Morepen will meet theirs. But Hydroxy and Meelung seem to be doing OK. As always, as Aquae S says, seeing is believing. I am hoping the trading update (exp later in Mar) will confirm improving numbers **. But if not it will be one step forward... And even with improved numbers, still quite a way from profitability.

Last two HY revenues were c. £600k. I'd hope for a good uplift on that for HY2 in 25. So perhaps even as much as £1.5m for FY 25. But that is indeed a hope and figures could easily disappoint again.

SweetBiotix is the unknown , not least in terms of coming to market.

One good initiative by the company is their new Q&A facility on the website. Prompt responses to most questions. So they're not hiding away which shows a degree of confidence. Cheers. MU.

Just on the Amazon data

Looks like £18 to £25 for a months supply

Retail price per sachet 67p

Bulk ingredient cost to OPTI from KAG India: estimated pence per gram

Gross margin on D2C ecommerce: 70%+ — consistent with what OPTI reports

The consumer is paying £18-25/month for a natural GLP-1 alternative versus £149-399/month for Wegovy in the US.

Amazon growth was 87% from a low base

Any views ?

OPTI has a full dedicated Amazon storefront with multiple live product lines, all sold by Optibiotix directly via Amazon Fulfillment (FBA):

∙ SlimBiome sachets (GLP-1 Safe Alternative branding) — in stock, active reviews into 2025

∙ SlimBiome High Fibre Prebiotic Gummies — sold by Optibiotix, fulfilled by Amazon, with the gummies carrying Amazon’s Choice badge and reviews as recently as March 2025

∙ Soups, shakes, and other formats also listed

Comments look positive as well

Note the product is now marketed explicitly as a “GLP-1 Safe Alternative” — right there in the product title on Amazon. That’s a deliberate positioning shift for people looking for Ozempic/Wegovy alternatives.

Just on HB

H&B discontinued the SlimBiome brand but kept the SlimBiome ingredient — reformulating it into their own SlimExpert house brand. From OPTI’s perspective this is arguably better:

∙ H&B is investing in marketing SlimExpert themselves, rather than OPTI having to fund brand-building

∙ H&B carries the stock risk and retail execution risk

∙ OPTI sells the ingredient in bulk regardless of which brand name is on the packet

With just 5 staff this looks smart

Chances are that they have done a small number of volunteers already because the methodology uses only product use by mouth as an additive to normal diet content.

Skid , I take your point that the trial might not be big enough to match all characteristics, but I expect they'll try and match both groups as far as possible. The overall sample size of 30 in each group is sufficient to be able to test for statistically significant difference between groups. But not for sub groups.

I don't think 60 (taking and placebo) would be a large enough population to be statistically accurate - need to have a the populations correct as well (age, sex, general health, specific condition) - one bed blocker on either side skews the result. Hopefully some more joined up thinking in the health service, provide decent nutrition costing a few quid to get people out a day early is a non brainer. Have a friends daughter who is a dietician (not nutritionist) in and NHS hospital.

If only OPTI had an ex health government minister as a non exec to have done all this stuff a few year ago, they could be reaping the benefits now.

Hi, This is a NHS study and will have routinely gone through assessment of the number of participants required to show a statistical difference to get approval and funding. This looks a really exciting study at the leading edge of NHS research into improving NHS outcomes and cost savings. Nice to see. As the RNS suggests it may open up another revenue stream which could be substantial if WellBiome shows an effect.

Lord, although apparently small, this is a usual sample size of two groups of 30. It just means that the difference in any effect between placebo group and those taking WellBiome will need to be bigger than if a larger sample size was used.

...with only 1% raise ... there must be a bigger interest to keep it down then to have this raise to subsequent levels where people put their savings few years back

RNS Number : 0691U

OptiBiotix Health PLC

24 February 2026

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

Clinical trial to evaluate the effect of WellBiome® on surgical outcomes and NHS cost savings

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and

food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the commencement of a

clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac

surgery outcomes and potential NHS cost savings.

A number of studies (Ardema 2019, Xia 2021) have suggested a decrease in microbial diversity and abundance post-surgery

may increase hospital stays and that prebiotics like WellBiome, which increase microbial diversity and abundance and have

systemic anti-inflammatory effects, may improve surgical outcomes.

This double blind, placebo-controlled study of up to 60 patients is designed to evaluate the effect of six-week pre-operative

supplementation on time spent in intensive care, length of hospital stay, and the incidence of post-operative complications.

The study includes a cost savings analysis to identify any potential cost savings to the NHS and inform the future use of

prebiotics like WellBiome in improving health outcomes and cost savings.

Click on Q&A tab at foot of page

This in response to "will there be an update for FY 2025 sales in the next few weeks?" 17/2

https://optibiotix.com/7326843#question-156441

Sp1. No you haven't really missed anything. Though recently (last year) Opti gave some numbers for what Dr Morepen were forecasting. And these seem more than a bit optimistic. And it is the overoptimism that has been part of the problem. In the early days of commercialisation of SlimBiome, etc we were told to expect partners in 3 groups of revenue. £250k, £500k and £1m / year brackets. These haven't materialised in any great numbers. And more importantly, we haven't held on to many partners, so revenues haven't been cumulative.

The other issue is the long awaited "imminent " commercialisation of SweetBiotix. A product backed by science and trials but never quite seeming to get to market.

In addition, due to admin costs and lack of appreciable revenue, the company is far from profitable. Based on last FY Opti would need £3.5-4m revenue to break even. So they have had to sell down the stake in SBTX. Not necessarily a bad thing but not popular with LTHs. Given the drama at SBTX over the last week, this avenue is closed for the foreseeable.

It does seem like the 1st generation products are gaining more traction. But I'm awaiting confirmation of this in FY update, likely in March.

One positive is the ability to ask questions directly to the company through a Q&A tab on website. Very prompt responses. And worth a look to see what's been asked so far.

I haven't given up on Opti but many have. I'm down a fair bit on my modest holding 20k shares left. Good luck. MU.

Hi,

I have looked back over all the RNS's and annual/interim reports and cant seem to find any 'missed financial target'. This seems to be because they havent given any financial forecast 😊 -which is common for AIM. I can see BB's giving forecasts but nothing from the company. Have I missed something.

Adyan - agreed. My post was slightly tongue in cheek, though they could perhaps have been slightly more specific - eg “we anticipate our cash position being more than sufficient to cover the current FY” (assuming that’s the case of course!

I guess by stressing that all divisions should reach breakeven by FY end, they’re implying this anyway. Mind, we have had similar (missed) targets from them in the past, so let’s just wait & see …..

That is reassuring. I don't have an issue with them using currently, as you cannot totally rule it out and no company would ever say I 100% won't sell SBTX shares for X years or such.

Though I've not been keen on them selling the SBTX shares, I do think it has greatly prevented us from being diluted otherwise with the low share price that OPTI has been for over the past year and more, it could have been a significant dilution.

Hi, I suspect the NOMAD has been behind the over use of currently as they like to qualify every statement.